CONTENTS 目錄 2 Financial Highlights 財務摘要 3 Corporate Profile 公司簡介 7 Management Discussion and Analysis 管理層討論與分析 64 Corporate Governance and Other Information 企業管治及其他資料 80 Review Report 審閱報告 82 Consolidated Statement of Profit or Loss and Other Comprehensive Income 綜合損益及其他全面收益表 84 Consolidated Statement of Financial Position 綜合財務狀況表 86 Consolidated Statement of Changes in Equity 綜合權益變動表 88 Consolidated Cash Flow Statement 綜合現金流量表 90 Notes to the Unaudited Interim Financial Reports 未經審核中期財務報告附註 125 Corporate I ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 有關通函、通告及代表委任表格之澄清 及 於二零二五年九月五日舉行之 二零二五年第一次臨時股東大會投票表決結果 茲提述(i)廣東東陽光藥業股份有限公司（「本公司」）日期為二零二五年八月十九日 的通函（「通函」）；(ii)日期為二零二五年八月十九日的二零二五年第一次臨時股東 大 會通 告（「通 告」）；及 (iii) 本公 司於 臨時 股 東大 會上 使用 的代 表委 任 表格（「代 表 委任表格」）。除文義另有所指外，本公告所用詞彙與通函、通告及代表委任表格 所界定者具相同涵義。 有關通函、通告及代表委任表格之澄清 本 公 司 謹 此 澄 清 ， 截 至 本 公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣東東陽光藥業股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06887 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 112,712,832 RMB | | | 1 RMB | | 112,712,832 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 112,712,832 RMB | | | 1 RMB | | 112,712,832 | 備註： 第 1 頁 共 11 頁 v 1.1.1 FF3 ...

Group 1 - The Hang Seng Index fell by 0.4%, while the Hang Seng Tech Index decreased by 0.54%, with a total turnover of 152 billion HKD in the Hong Kong stock market during the morning session [1] - The Hang Seng Biotechnology Index rose by 1%, with notable gains from companies such as MicroPort Scientific Corporation (02252) up by 10%, and Four Seasons Medicine (00460) up by 8% [1] Group 2 - MicroPort Scientific Corporation (02252) saw a rise of over 10%, indicating renewed interest in the robotics industry and steady progress in the company's commercialization efforts [2] - Dongyang Sunshine Pharmaceutical (06887) increased by nearly 7%, reporting a mid-term gross profit of 1.468 billion HKD, with key data on Ifenprodil presented at the US IPF summit [2] - Chuangsheng Group-B (06628) surged over 28%, with a mid-term net loss narrowing by 17.9%, and TST001 research data making its debut at ASCO [2] - Kingsoft Holdings (03918) rose by over 6%, with first-half performance exceeding market expectations, although uncertainties remain regarding the Naga3 project according to Citigroup [2] - Green Power Environmental (01330) increased by over 7%, with a 24.49% year-on-year increase in net profit attributable to shareholders, driven by its gas supply business [2] - Hylink Technology (01860) rose by 7.9%, with first-half revenue increasing by 40% year-on-year, and institutions optimistic about the continued release of the Mintegral platform's flywheel effect [2] - Zhi Zi Cheng Technology (09911) rose by over 6%, with first-half net profit nearly doubling, and the group's gross profit margin expected to improve significantly year-on-year [2] - Four Seasons Medicine (00460) rose by over 7%, achieving profitability in the first half and making substantial progress in its AI + medical beauty strategic layout [2] - Guofu Quantum (00290) increased by 6.86%, with a cumulative increase of nearly 1.8 times this year, collaborating with Huajian Medical to advance RWA ecosystem construction [2] - New Idea Network Group (01686) fell by over 17% post-results, with annual net profit increasing by 8% to 979 million HKD [2]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) reported a revenue of 1.938 billion RMB for the first half of 2025, with a gross profit of 1.468 billion RMB, indicating a significant impact from the reduced flu epidemic compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 1.938 billion RMB and a gross profit of 1.468 billion RMB for the first half of 2025 [1] - The sales revenue from the oseltamivir product, a preferred flu medication, was 1.301 billion RMB, reflecting a decline due to the flu epidemic's slowdown [1] Group 2: Product Development and Innovation - Dongyang Sunshine Pharmaceutical showcased its innovative anti-fibrotic drug, HEC585, at the 9th Idiopathic Pulmonary Fibrosis (IPF) Summit held in Boston from August 19 to 21, 2025 [1] - HEC585 is the first domestically developed IPF new drug to enter Phase III clinical trials and has potential applications for progressive fibrosing interstitial lung disease (PF-ILD), hepatitis B liver fibrosis, and interstitial pneumonia [2] - The drug works by simultaneously inhibiting the release of TNF-α and TGF-β1, blocking the TGF-β1-Smad signaling pathway, and regulating various signaling pathways to form a comprehensive anti-fibrotic network [2]

Core Insights - Dongyang Sunshine Pharmaceutical has established a dedicated liver disease team to accelerate the commercialization of innovative hepatitis C drugs [2][3] - The company has received approval for two hepatitis C drugs, Dongweizhuo and Dongyinghe, which are designed for the treatment of chronic hepatitis C virus infections [2][3] - The company is working to reduce its reliance on its flu drug Oseltamivir, which has seen a decline in sales contribution from 81.2% in 2022 to an expected 64.2% in 2024 [2][3] Company Developments - The newly formed liver disease team operates across seven major business areas, including Shanghai, Guangzhou, and Beijing, with a total workforce of over 100 [3] - Dongyang Sunshine Pharmaceutical has three liver disease drugs approved for market, addressing a significant public health issue in China where approximately 10 million people are infected with hepatitis C [3] - The company is attempting to push its hepatitis C drugs into the new round of national medical insurance catalog [4] Market Context - The market for hepatitis C treatments is competitive, with 17 direct-acting antiviral drugs (DAAs) approved in China, eight of which are included in the national medical insurance directory [3] - Dongyang Sunshine Pharmaceutical's ability to succeed in the hepatitis C market will depend on its commercialization capabilities [3]

Core Viewpoint - Dongyangguang Pharmaceutical is restructuring its sales team to focus on liver disease, aiming to accelerate the commercialization of innovative hepatitis C drugs [3][5]. Group 1: Company Developments - In August, Dongyangguang Pharmaceutical established a dedicated liver disease team to enhance the commercialization of its hepatitis C treatments [3]. - The company has received approval for two innovative hepatitis C drugs, Dongweizhuo (Nafamostat) and Dongyinghe (Echocardiography), which can treat chronic hepatitis C virus infections in adults [3][4]. - The sales of the flu drug Oseltamivir, known as Kewai, have decreased from 81.2% of total sales in 2022 to 64.2% in 2024, indicating a shift in the company's revenue reliance [3]. Group 2: Market Context - There are approximately 10 million hepatitis C patients in China, but the diagnosis and treatment rates are low, presenting a significant public health challenge [5]. - Dongyangguang Pharmaceutical's new hepatitis C drugs provide additional treatment options for patients, but the company faces competition from other manufacturers in the hepatitis C drug market [5]. - Currently, there are 17 approved direct-acting antiviral drugs (DAA) for chronic hepatitis C in China, with eight included in the national medical insurance catalog [5].

Summary of Key Points Core Viewpoint - Dongyangguang Pharmaceutical (06887.HK) reported a significant decline in revenue and profit for the six months ending June 30, 2025, indicating potential challenges in its business operations [1]. Financial Performance - Revenue for the period was RMB 1,937.67 million, a decrease of 24.95% year-on-year [1]. - Gross profit amounted to RMB 1,467.61 million, reflecting a year-on-year decline of 28.12% [1]. - The total loss attributable to equity holders of the company was RMB 54.27 million, a decrease of RMB 192.90 million compared to a profit of RMB 138.63 million in the same period last year [1]. - Basic and diluted loss per share was RMB 0.11 [1].

Core Viewpoint - Dongyangguang Pharmaceutical (06887) reported a mid-year revenue of 1.938 billion RMB and a gross profit of 1.468 billion RMB, highlighting its diversified market strategy and focus on enhancing the competitiveness of its core products [1] Group 1: Financial Performance - The company achieved a revenue of 1.938 billion RMB and a gross profit of 1.468 billion RMB for the mid-year of 2025 [1] - The sales of Oseltamivir, a key product for flu treatment, reached 1.301 billion RMB, although it faced some impact due to a slowdown in flu cases compared to the same period last year [1] Group 2: Strategic Initiatives - The company is implementing a diversified market strategy, which includes ongoing academic promotion activities and optimizing channel construction to enhance the market competitiveness and commercial value of its core products [1] - Increased investments in advertising, marketing activities, and patient education are aimed at improving brand awareness of core products [1] - Strengthening strategic partnerships with internationally renowned companies to accelerate the development and commercialization of innovative drugs and biopharmaceuticals in international markets [1] Group 3: Research and Development - The company focuses on core therapeutic areas such as infections, chronic diseases, and oncology, adhering to an independent innovation research and development strategy [1] - Dongyangguang Pharmaceutical has over 150 approved drugs, with 3 innovative drugs already on the market and 100 drugs under research, including 49 first-class innovative drugs [1] - Among the first-class innovative drugs under research, there is 1 drug for which a New Drug Application (NDA) has been submitted to the regulatory authority, and 10 drugs are in Phase II or III clinical trials [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 的 中 期 業 績 公 告 財 務 摘 要 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月，本 集 團 錄 得： 中 期 股 息 • 董 事 會 議 決 不 派 付 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 的 中 期 股 息（截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月：無）。 – 1 – • 營 業 額 為 人 民 幣1,937.67百 萬 元，較 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 減 少24.95%。 • 毛 利 為 人 民 幣1,467.61百 萬 元，較 截 至 二 ...